Nemolizumab is under clinical development by Galderma and currently in Phase III for Pruritus. According to GlobalData, Phase III drugs for Pruritus have a 64% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how Nemolizumab’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Nemolizumab overview

Nemolizumab(Mitchga) is monoclonal antibody against it is formulated as freeze dried powder for solution for subcutaneous route od administration. Mitchga is indicated for the treatment of itching associated with atopic dermatitis (AD) for adults and children 13 years and older.

Nemolizumab (CIM-331) is under development for the treatment of prurigo nodularis, atopic dermatitis, hemodialysis participants with severe pruritus, prurigo nodularis patients with moderate to severe pruritus and systemic sclerosis (scleroderma). The drug candidate is administered as a subcutaneous solution. It is an anti-IL-31 receptor alpha humanized monoclonal antibody. It is a new molecular entity (NME). It is developed based on proprietary antibody engineering technology ACT-Ig.

Galderma overview

Galderma is a pharmaceutical company that develops and markets medical and consumer skin health products. Galderma provides prescription drugs and aesthetic solutions for the treatment of various skin conditions such as acne, rosacea, psoriasis and steroid-responsive dermatoses, nail mycosis, pigmentary disorders, skin cancer, atopic dermatitis, and sun protection among others. Its major brands include Epiduo, Differin, Oracea, Loceryl, Metvix, Azzalure/Dysport, Mirvaso, Soolantra, Restylane, Cetaphil, and Emervel. The company has its research and development centers and manufacturing sites in Asia-Pacific, the Middle East, Europe, Africa, and North and Latin America. Galderma is headquartered in La Tour-de-Peilz, Vaud, Switzerland.

For a complete picture of Nemolizumab’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.